How We're
Building It
A Women's Health Diagnostics Biotechnology Company Building the Next Generation of Accessible Molecular Testing
A clear path from research to real-world access
Non-Invasive Sample Collection
A non-invasive sample collected during a routine clinical visit. No surgery required. The sample carries biological information about what is happening throughout the body.
Biomarker Discovery
Candidate biomarkers are identified from biological data and evaluated against strict criteria. A biomarker qualifies only if it consistently distinguishes disease from non-disease across independent samples.
Assay Development
Qualifying biomarkers are translated into a reproducible laboratory test, called an assay. This converts the finding into a standardized procedure that produces consistent results across different labs and patient samples.
Clinical Validation
The assay is tested on an independent set of patient samples, ones never used during development. This confirms the test performs in the real world, not just under the conditions it was built for.
Clinical Availability
Only after meeting pre-defined accuracy thresholds does the test move toward patients. The goal is a tool that fits into a routine appointment and supports clinical decision-making without requiring surgery.
Behind every diagnostic delay is a woman who deserved a better answer.
This is for her.
The biology
leads the science
A decade without answers is not acceptable. Veridyn exists to change that by building the gold-standard non-invasive diagnostic for endometriosis, one that meets the rigorous scientific and clinical standards that title requires.
We get there by studying the biology of endometriosis directly and letting the evidence define the test. The candidate markers that advance are the ones that hold up consistently across independent samples. The ones that do not, do not advance. That is what it takes to build something clinicians can trust and patients can rely on.
Built differently,
for a reason
The diagnostic gap in endometriosis is not new. What has been missing is a development approach rigorous enough to close it.
Results-Led Development
We design experiments around a clear biological hypothesis and accept what the data shows. If the hypothesis is wrong, we revise it. A diagnostic built on honest signals is the only kind that holds up in clinical practice and earns the trust of the physicians and patients who rely on it.
Equity by Design
Diagnostic delay is not equal across populations. Women of color face longer waits, more dismissals, and less representation in the research shaping clinical guidelines. Veridyn's validation cohort is structured from the outset to reflect diverse populations, not added as an afterthought once the core study is complete.
Built to Expand
The validated framework for endometriosis is designed to extend to additional women's health conditions where the same diagnostic gap exists. Each indication builds on the same evidence standard, without starting over from scratch.
Our development path
Each phase has defined criteria that must be met before the next begins. Progress is transparent and results are shared at publication.
Pilot
Signal detection and specimen type selection. Candidate biomarkers identified from patient samples. Go/no-go decision based on pre-specified criteria before any further development begins.
Verification
The leading biomarker panel is locked and converted into a reproducible laboratory assay. No further changes to the panel are permitted once this phase begins. Confirmed on a larger independent sample set.
Validation
Prospective validation across a diverse patient population enrolled through clinical partners. This phase establishes whether the test is ready for clinical use and regulatory review. Results are published regardless of outcome.
Launch
The validated test becomes available to ordering physicians through a certified laboratory. Revenue from this phase supports ongoing regulatory work toward full FDA clearance and expansion to additional indications.
The framework is
built to grow
Endometriosis is the first indication. Once validated, the same architecture is designed to extend to additional women's health conditions where the same diagnostic gap exists.